Related Experiment Video
Updated: Jan 17, 2026
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
Design, development, and therapeutic applications of PARP-1 selective inhibitors
Yue Xu1, Xiangqian Li1,2, Yuanyuan Zhao1
1State Key Laboratory of Microbial Technology, Shandong University, Qingdao, Shandong, P. R. China.
Abstract:
Poly(ADP-ribose) polymerase (PARP) plays a key role in DNA damage repair and has become a critical target for tumor therapy. In recent years, several PARP inhibitors, such as Olaparib and Niraparib, have achieved clinical success in breast cancer susceptibility genes (BRCA) mutant tumors by exploiting the synthetic lethality of homologous recombination-deficient cancers. However, problems have emerged in clinical application, such as hematologic toxicity, which may be related to the lack of subtype selectivity of PARP-1/-2. Selective inhibitors of PARP-1 that can overcome toxicity have emerged as a new strategy for PARP inhibitor development. In this review, we first reveal the conformational heterogeneity of the PARP-1/-2 active region through homology comparison and systematically explain the spatial topological characteristics of its selective binding pockets. Then, the structure-activity relationships of 14 reported selective inhibitors of PARP-1 are analyzed to reveal the key pharmacophores occupying the active region, as well as to characterize the specific groups bound to the selective binding domain. Finally, we discuss the structural requirements of selective PARP-1 inhibitors and propose the "secondary site contact" design strategy for the development of new PARP inhibitors.
Insights
Selective Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors offer a new strategy to overcome toxicity associated with current PARP inhibitors. This review analyzes structural requirements for developing effective and selective PARP-1 inhibitors.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Poly(ADP-ribose) polymerase (PARP) is crucial for DNA repair and a target in cancer therapy.
- PARP inhibitors like Olaparib are effective in BRCA-mutant tumors but cause hematologic toxicity due to lack of subtype selectivity.
- Selective PARP-1 inhibitors are being developed to mitigate toxicity and improve therapeutic outcomes.
Purpose of the Study:
- To analyze the structural basis for selective inhibition of PARP-1.
- To identify key pharmacophores and binding interactions for selective PARP-1 inhibitors.
- To propose a design strategy for novel PARP inhibitors with improved safety profiles.
Main Methods:
- Homology comparison to reveal conformational heterogeneity of PARP-1/-2 active regions.
- Systematic analysis of spatial topological characteristics of selective binding pockets.
- Structure-activity relationship analysis of 14 reported selective PARP-1 inhibitors.
Main Results:
- The study elucidates the conformational heterogeneity of the PARP-1/-2 active region.
- Key pharmacophores and specific binding groups for selective PARP-1 inhibition were identified.
- Structure-activity relationships highlight critical interactions within the selective binding domain.
Conclusions:
- Understanding the structural nuances of PARP-1 is essential for developing selective inhibitors.
- The identified pharmacophores and binding interactions guide the design of next-generation PARP inhibitors.
- A "secondary site contact" strategy is proposed for developing safer and more effective PARP-1 inhibitors.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
01:02Long-patch Base Excision Repair